Format

Send to

Choose Destination
Cytojournal. 2017 Feb 24;14:4. doi: 10.4103/1742-6413.200935. eCollection 2017.

Detection of BRAF mutation in the cytocentrifugation supernatant fluid from fine-needle aspiration of thyroid lesions may enhance the diagnostic yield.

Author information

1
Address: Department of Pathology University of Central Florida College of Medicine, Orlando, FL, USA.
2
Department of Internal Medicine, Florida Hospital, Orlando, FL, USA.
3
Department of Pathology and Laboratory Medicine, Florida Hospital, Orlando, FL, USA.
4
Address: Department of Pathology University of Central Florida College of Medicine, Orlando, FL, USA; Department of Pathology and Laboratory Medicine, Florida Hospital, Orlando, FL, USA.

Abstract

OBJECTIVE:

BRAF mutations using cellular DNA from fine-needle aspiration (FNA) specimens are commonly used to support the diagnosis of papillary thyroid carcinoma (PTC). The goal of this study was to preliminarily evaluate the diagnostic utility of detecting BRAF mutations in the routinely discarded FNA specimen supernatant fluid.

MATERIALS AND METHODS:

Seventy-eight FNAs of thyroid lesions were evaluated for BRAF mutations using both cellular and supernatant DNA. BRAF mutation data were correlated with cytology and surgical pathology.

RESULTS:

Of the 78 samples evaluated, 68 (87%) had amplifiable DNA in the supernatant with 2 (3%) positive for BRAF mutations. These two samples showed no mutations in the cellular counterpart. Among the 11 samples showing morphologic findings (FNA/surgical pathology) suspicious/diagnostic of PTC, 6 (55%) samples (one supernatant and five cellulars) were positive for BRAF mutations. This suggests that testing supernatant DNA in FNA specimens may increase the diagnostic yield by 1/11 (9%) in this setting.

CONCLUSIONS:

The vast majority of routinely discarded FNA supernatants contain amplifiable DNA. In addition, profiling the mutations of BRAF and other genes using supernatant DNA may provide valuable diagnostic information to assist the diagnosis of PTC in patients with clinical/morphologic findings suspicious for malignancies and cellular DNA showing no mutations.

KEYWORDS:

BRAF; fine-needle aspirate; fine-needle aspiration supernatant; papillary thyroid carcinoma

Supplemental Content

Full text links

Icon for Medknow Publications and Media Pvt Ltd Icon for PubMed Central
Loading ...
Support Center